• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biovica International

0.36 SEK

+0.28 %

Less than 1K followers

BIOVIC B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.28 %
+1.97 %
+31.64 %
-2.16 %
-29.02 %
-47.40 %
-93.67 %
-98.97 %
-96.47 %

Biovica International is a pharmaceutical company that focuses its research on cancer treatment. The company develops blood-based biomarker tests to monitor and evaluate cancer treatments. The tests analyze the risk of developing the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main focus is on the treatment of breast cancer. Biovica International was founded in 2008 and is headquartered in Uppsala.

Read more
Market cap
105.67M SEK
Turnover
488.61K SEK
Revenue
8.62M
EBIT %
-995.82 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Biovica is a Swedish biotechnology company founded in 2009. It was listed on the stock exchange in 2017. Its main product is the DiviTum TKa test: https://divitum.com/, which is a biomarker test that monitors and predicts treatment response in breast cancer. They received FDA approval...
8/31/2025, 1:45 PM
by OSAKEURPO
5
Biovica Q1 Interim report May 2025 – July 2025 - Biovica International AB 11.9 julkaistu osavuosi Tappio pieneni pikkaisen, mutta ei vielä merkittävää parannusta. Lisää myyntiä vaaditaan, että paastään luvattuun 2026 loppuvuoden voitolliseen tulokseen. Mielenkiinnolla seurailen mit...
9/18/2025, 12:09 PM
by Waldeboy
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.6
2026

Annual report '26

10.9
2026

Interim report Q1'27

16.9
2026

General meeting '26

Regulatory press release5/28/2026, 6:30 AM

New phase III translational data show DiviTum® TKa captures treatment-specific biological response in metastatic breast cancer

Biovica International
Regulatory press release5/26/2026, 6:45 AM

Biovica receives expanded work order from clinical-stage oncology company for next-generation CDK inhibitor program

Biovica International
Regulatory press release5/5/2026, 7:30 PM

Biovica International AB announces change in executive management

Biovica International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/30/2026, 8:00 AM

New ESMO data highlights TKa across multiple treatment settings

Biovica International
Regulatory press release4/16/2026, 6:00 AM

Theis Kipling to Assume Role as CEO of Biovica on May 1, 2026

Biovica International
Regulatory press release4/7/2026, 6:30 AM

Theis Kipling new CEO for Biovica

Biovica International
Press release3/23/2026, 2:32 PM

Redeye: Biovica (Q3 Review): Execution key as revenue drivers emerge

Biovica International
Regulatory press release3/18/2026, 7:05 AM

New AACR data expand evidence for TKa in immunotherapy-treated patients and CDK inhibitor dose optimization

Biovica International
Regulatory press release3/18/2026, 7:00 AM

Biovica International AB - Q3 Interim report Nov 2025-Jan2026

Biovica International
Regulatory press release3/9/2026, 4:00 PM

Nomination Committee for Biovica International AB for the 2026 Annual General Meeting

Biovica International
Regulatory press release3/5/2026, 2:30 PM

Biovica Announces Planned CEO Succession; Anders Rylander to Step Down During 2026

Biovica International
Regulatory press release2/12/2026, 7:30 AM

Newly published data reinforce robust prognostic associations for DiviTum® TKa in metastatic breast cancer

Biovica International
Regulatory press release1/27/2026, 7:30 AM

Strong DiviTum TKa results published in JCO Precision Oncology

Biovica International
Press release1/8/2026, 7:08 AM

Redeye: Biovica (Q2 Review) - Setback on Timing, not on Long-Term Opportunity

Biovica International
Regulatory press release12/18/2025, 7:30 AM

Biovica International AB - Q2 Interim report Aug- Oct 2025

Biovica International
Regulatory press release12/15/2025, 7:30 AM

Biovica signs client bill agreement with leading U.S. NCI-designated Cancer Center

Biovica International
Regulatory press release11/26/2025, 7:45 AM

Two new studies with DiviTum TKa presented at SABCS 2025

Biovica International
Regulatory press release9/23/2025, 10:00 AM

Announcement from the annual general meeting in Biovica International AB

Biovica International
Press release9/19/2025, 8:21 AM

BioStock: SEK 122 million gives Biovica the power to scale up globally

Biovica International
Press release9/12/2025, 2:21 PM

Redeye: Biovica Q1 Update - Capitalised but the launch is still not in full swing

Biovica International